Observational studyFuture oncology (London, England)2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.
Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04649359 (MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Magnetismm-3 an open-label, multicenter, non-randomized phase 2 study of elranatamab (pf-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cd38 antibody
Who cites it
1 citing paper in PubMed.
- Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimElranatamab is a bispecific antibody currently approved in the United States (US) for the treatment of relapsed/refractory multiple myeloma (MM). Given its recent approval, real-world data are limited.
methodsResults from two real-world (RW) studies using administrative claims (ALTITUDE-1) and fee-for-service data (ALTITUDE-2) are collectively reported here. US patients with MM who initiated elranatamab after August 2023 were included and followed through September/October 2025. Patient characteristics, clinical history, treatment patterns, and effectiveness outcomes were reported.
resultsOne hundred and eighty-three and 391 patients were included from ALTITUDE-1 and -2, respectively. Median ages were 73 and 75, 43.2% and 33.0% were penta-drug exposed, and 17.5% and 21.0% were previously BCMA-exposed, respectively. RW treatment patterns showed less frequent dosing (27.9 and 27.1 elranatamab vials used per year) compared with expected on-label dosing (39 vials per year). Neither median time-to-next-treatment or death or median overall survival were reached; landmark analyses for each study estimated 70.0% (ALTITUDE-1) and 60.7% (ALTITUDE-2) of patients alive at 18 months.
conclusionUS patients treated with elranatamab in the RW setting were heavily pre-treated. RW treatment patterns suggest less frequent administration of elranatamab compared with the label and effectiveness consistent with clinical trial results (MagnetisMM-3 trial [NCT04649359]).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.